Amplia Therapeutics Ltd INNMF
$0.11 $0.11
Last Updated: Aug 21, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
INNMF Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Amplia Therapeutics Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Amplia Therapeutics Ltd. Stock Analysis INNMF
United States Health Care Micro Cap Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Amplia Therapeutics Ltd (INNMF) Chart
Financial Metrics & Statements of Amplia Therapeutics Ltd (INNMF)
FAQ's for Amplia Therapeutics Ltd (INNMF)
- As of August 2026, Amplia Therapeutics Ltd INNMF is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Amplia Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Amplia Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Amplia Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Amplia Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Amplia Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Amplia Therapeutics Ltd (INNMF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
